Aequo's attorneys have successfully defended the rights of the Ukrainian pharmaceutical company "Darnitsa" to the shares of the Borshchahivskiy chemical-pharmaceutical plant in the Supreme Court.

On October 29, 2020, the Supreme Court granted the cassation appeal of the pharmaceutical company "Darnitsa" and cancelled the groundless resolution of the Northern Commercial Court of Appeal dated August 25, 2020 concerning acquisition of shares of the SIC "Borshchahivskiy chemical-pharmaceutical plant" by "Darnitsa" at the privatization auction in 2015, and ultimately confirmed "Darnitsa’s" right to the shares.

The resolution of the Supreme Court is final and not subject to further appeal. Earlier, the Supreme Court also confirmed the validity of the decision of the Antimonopoly Committee of Ukraine on granting “Darnitsa” merger clearance by acquiring the abovementioned shares.

The pharmaceutical company "Darnitsa" acquired a stock of 3,100 shares (29.95% of the charter capital) of the SIC "Borshchahivskiy chemical-pharmaceutical plant" from Department of Kyiv Communal Property at the privatization auction on March 20, 2015.

Yevgen Levitskyi, Aequo’s counsel, dispute resolution, and Oleksandr Zubrytskyi, associate, dispute resolution worked on the case.